If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
130
results.
Updated on
06/11/2025 [07:05:00]
Results 75 to 100 of 130
Absstract of: KR20250142840A
본 개시 내용에 따르면, 코로나 바이러스와 같은 검출 대상 바이러스의 RNA가 포집 프로브(capture probe)인 금-DNA-양자점에 부착되어 DNA-RNA 부합체를 형성한 다음, 이중나선 특이적 핵산분해효소(Duplex-specific nuclease; DSN)에 의하여 DNA가 소화됨에 따라 포집 프로브로부터 양자점의 금속 이온이 방출되고, 이와 같이 방출된 양자점의 금속 이온을 센싱함으로써 시료 내 검출 대상 바이러스(구체적으로, 코로나 바이러스)를 정량적 및/또는 정성적으로 검출하는데 적합한 복합 전극 및 센서가 기재된다.
Absstract of: US12427177B1
The present invention relates to a composition and use thereof directed towards treating various health ailments, such as skin and respiratory problems and various infections. More particularly, the present invention relates to a lime sulfur solution and use thereof, of varying percentages, directed towards improving vision and treating various skin problems and infections, such as toenail fungus, athlete's foot, jock itch, skin psoriasis, eczema, vaginal yeast infections, head or beard dandruff, respiratory infections, itching of the skin (particularly of the hands), acne (facial and/or body acne), poison ivy, insect bites, head and body lice, crabs, cuts, treating wounds infected by staff and/or MRSA (methicillin-resistant Staphylococcus aureus) bacteria, tongue thrush, ringworm, penis foreskin infections, skin tags, and is also directed towards treating various respiratory infections (such as pneumonia, chronic obstructive pulmonary disease (COPD), asthma, and Covid-19 infections). The present invention also relates to use of the aforementioned composition and solution as a disinfectant in gyms, spas, saunas, for professional athletes, or as a body and/or hair wash.
Absstract of: US12427191B1
A SARS-CoV-2 immunotherapeutic targeted fusion protein regimen or vaccine in which the extracellular domain (ecd) of the CD40L immunostimulatory protein, is attached individually to mRNA encoding a Selected Fragment of the Spike Protein (SFSP), representing a different functional feature and a different domain or domain region, or both of the Spike Protein, to generate 7 distinct SFSP/ecdCD40L translation units, each translation unit being converted into a SFSP/ecdCD40L fusion protein regimen or vaccine and all combined into a single fusion protein mixture or composition for injection, preferably inter-muscularly (im). Each fragment or peptide is designed to activate a humoral and cellular immune response to a different SFSP. Each SFSP fragment or peptide, as a vaccine strategy for the SARS-CoV-2 virus, has the capability to suppress the emergence of immunological escape mutants. The fusion protein mixture or composition of multiple fragments or peptides could be incorporated in any one of several delivery platforms such as an adenoviral expression vector or an mRNA platform.
Absstract of: MY210499A
The present invention relates to the anti- SARS-CoV-2-infection protein and vaccine, and belongs to the field of medicine. Due to the lack of efficient drugs for SARS-CoV-2 infection prevention and treatment in the prior art, the present invention provides an anti-SARS-CoV-2-infection protein, which contains a domain that binds with the angiotensin-converting enzyme 2 (ACE2) receptor as contained in the SARS-CoV-2 S protein. One the other hand, the present invention also provides a vaccine for SARS-CoV-2 infection prevention and/or treatment, which comprises the anti-SARS-CoV-2-infection protein as well as the pharmaceutically acceptable excipient or auxiliary ingredient. The present invention mainly induces the production of antibodies in the body for immunoreaction and blocks the binding the SARS-CoV-2 S protein and the ACE2 receptor of the host cell, thus helping the host to fight against the corona virus infection. (Fig. 1)
Absstract of: US2025297314A1
The invention relates to an in vitro or ex vivo method for determining the risk of death in a subject infected with a respiratory virus, for example SARS-CoV-2, comprising a measurement, in a biological sample of said subject, of the level of expression of the CD74 gene; the invention also relates to associated kits.
Absstract of: US2025298008A1
The present invention uses ex vivo human airway cultures to assess the human transmissibility and replication competence of influenza and coronavirus strains. By comparing pandemic influenza A subtype H1N1 and highly pathogenic avian influenza H5N1 as reference strains, the transmissibility risk of various viruses was evaluated and categorized. Additionally, an in vitro model evaluated virus-induced impairment of alveolar fluid clearance (AFC) as an indicator of disease severity. The study revealed correlations between bronchus viral replication, human transmission, AFC impairment, and clinical disease severity across different influenza and coronavirus strains.
Absstract of: US2025297331A1
Methods are provided for detecting the presence of a specific genomic variant in a multiplex assay and distinguishing it from other genomic variants by interrogating one or more genomic loci specific to a particular genomic variant, and one or more semi-specific genomic loci present in in at least two genomic variants. The methods are useful for detecting a SARS-CoV-2 variant in a sample.
Absstract of: US2025297277A1
Provided herein are SARS-CoV-2 virus-like particles as well as methods and compositions for generating SARS-CoV-2 virus-like particles. The SARS-CoV-2 virus-like particles can load and deliver transcripts (including engineered transcripts that can include therapeutic agents) into cells expressing SARS-CoV-2 entry factors. The SARS-CoV-2 virus-like particles are also useful for detecting immune response in antibodies from subjects.
Absstract of: US2025297244A1
Compositions and methods for the diagnosis and treatment of severe Covid 19 and other inflammatory autoimmune disorders are disclosed.
Absstract of: US2025296936A1
The present disclosure relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Absstract of: US2025295759A1
The invention relates to a method of enhancing immunity, mRNA-based vaccines for SARS-COV-2 have demonstrated the enormous potential of mRNA therapeutics for safe and effective use in the general population. However, more recent studies have demonstrated decreasing vaccine effectiveness in terms of asymptomatic infection as well as symptomatic and severe infections starting around 4 months post second dose with mRNA-lipid nanoparticles (LNP) based regimens.
Absstract of: US2025295754A1
A method involving collecting viral particles from exhaled breath for developing oral vaccines against diseases like COVID-19. Infected individuals exhale breath into sterile equipment to separate viral particles through centrifuging and filtering, excluding saliva and other pathogens. The process avoids heat or methods that could destroy the viruses, ensuring the aerosol's vitality. Purified extracts, suspended in cold saline or water, undergo optional screening for contaminants and multiplication in sterile conditions. The final product is a quantified, purified aerosol extract of the virus, used for oral vaccine development.
Absstract of: US2025295657A1
Provided herein are methods of treating a patient, such as a human patient, having inflammation or an inflammatory disease or a disease in which inflammation is present, such as cardiovascular or vascular endothelium inflammation, such as pulmonary hypertension, restenosis, essential hypertension, atherosclerosis, stroke, sepsis, or a viral infection, such as a coronavirus infection, SARS-CoV-2. The methods comprise administering to the patient an amount of a compound as described herein effective to treat the patient. NCOA7-activating compounds and compositions also are provided. Also provided is a gene editing method of reducing inflammation or an inflammatory condition in a patient having a C at SNP rs 11154337, comprising editing the C to a G.
Absstract of: US2025295528A1
Disclosed herein are protective apparatuses, and associated systems, for minimizing the risk of transmission of SARS-CoV-2 and/or other infectious diseases between individuals in close proximity to one another including, for example, transmission through droplets projecting from the mouth or nasal region of an infected individual. Said apparatuses may comprise a substantially transparent shield component and a handle component comprising a connecting aspect. The protective apparatuses may comprise light emitting diodes and associated control means. The protective apparatuses of the present disclosure may further comprise a camera communicatively connected to a display screen.
Absstract of: US2025296985A1
The present invention relates to seven novel neutralizing human monoclonal antibodies (mAbs) THSC20.HVTR04, THSC20.HVTR06, THSC20.HVTR11, THSC20.HVTR26 THSC20.HVTR39, THSC20.HVTR55 and THSC20.HVTR88 and their nucleotide sequences isolated from a convalescent individual of Indian origin by antigen (RBD)-specific single B cell sorting and cloning of variable heavy and light IgG chain genes. The isolated mAbs demonstrate neutralization of wild type Wuhan strain and the following variants of concern: South African variant of concern (B.1.351), UK variant of concern (B.1.1.7), Brazilian variant of concern (PI), Delta (B.1.617.2) and Omicron (B.1.1.529) with exception of THSC20.HVTR39 unable to neutralize Gamma (P1). Of these THSC20.HVTR04 is able to potently neutralize Omicron BA.2 and BA.4/BA.5, THSC20.HVTR06 is able to neutralize Omicron BA.1, BA.2 and BA.5 with low potency, THSC20.HVTR11 potently neutralizes Omicron BA.1 and BA.2 and THSC20.HVTR26 neutralizes Omicron BA. 1 only with moderate potency. The present invention also discloses the binding affinity of the neutralizing mAbs to the receptor binding domain (RBD) representing Wuhan isolate (wild type). The present invention also, discloses the use of neutralizing monoclonal antibodies (mAbs) against SARS-CoV-2 for its diagnostic, prognostic, preventive and therapeutic purposes.
Absstract of: US2025296962A1
The present invention discloses an S-RBD trimer protein for a novel coronavirus. The trimer protein is composed of amino acid fragments at positions 319-537 in an RBD domain of an S protein of the novel coronavirus n a trimer form. A body is immunized with a vaccine prepared in the present invention taking the S-RBD trimer protein as an antigen and supplemented by an adjuvant, and then a hic neutralizing antibody for the novel coronavirus may be produced and may be used for treating and/or preventing novel coronavirus (SARS-CoV-2) infection and/or a novel coronavirus disease.
Absstract of: US2025298032A1
The present disclosure provides antibodies against chemokines, in particular to auto-antibodies against chemokines, nucleic acids encoding such antibodies and compositions comprising such antibodies. The present disclosure also provides a method for identifying (auto-)antibodies against chemokines, antibodies identified by said method and to the use of antibodies against chemokines as biomarkers, and for the treatment and diagnosis of diseases, such as COVID-19.
Absstract of: US2025295756A1
It is provided a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2′-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome.
Absstract of: US2025295757A1
The invention relates to a polynucleotide encoding an attenuated SARS-CoV-2 or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons. The polynucleotide may comprise further modifications and may be comprised in an attenuated SARS-CoV-2. The invention further relates to methods for production of the polynucleotide and pharmaceutical products, e.g. for medical use.
Absstract of: WO2025198176A1
The present invention relates to a method for analyzing a molecule-molecule interaction and a device for detecting substances that interfere with such interactions. For example, the present invention relates to a method for analyzing protein-protein interactions, more specifically the interaction between the spike protein of SARS-CoV-2 and its receptor, human ACE2 protein, and a device capable of detecting neutralizing antibodies generated by vaccination on the basis of the analysis.
Absstract of: ZA202403414B
The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.
Absstract of: WO2024105235A1
The disclosure relates to a pharmaceutical composition comprising human plasma-derived polyclonal, anti-SARS-CoV-2 hyperimmune globulins and to said pharmaceutical composition for use in the treatment of a SARS-CoV-2 Omicron variant infection. The disclosure also relates to a method for the preparation of a polyclonal, hyperimmune globulin composition anti-SARS-CoV-2.
Absstract of: GR1011042B
The invention relates to the composition and preparation of a spray product which is characterized by antiviral properties and is applied to the nasal cavity. The spray works by repelling the virus particles and preventing the interaction of the host receptors with viral proteins responsible for the entry of the virus particles into human cells. The essential oils of eucalyptus, cinnamon and lavender are known for their antiviral activity, when in the vapor state; therefore, they have been selected to "trap" and repel the virus particles before they enter the human body. In addition, it contains a plant component which creates a protective film on the nasal mucosa for preventing the entry of the virus particles into the human body. Specifically, it contains bergamot and tea tree oils which are known for their inhibitory effect against SARS-CoV-2 and H1N1, affecting the pathways of the infection mechanism. It also contains thyme essential oil which has a virucidal effect against SARS-CoV-2 and influenza virus. Finally, to create the protective film mentioned above, iota-carrageenan - a high molecular weight sulfated polysaccharide derived from red algae (Rhodophyceae)- chitosan and ulvans are also used. Its composition mainly targets influenza virus ( A and B type) , rhinoviruses and coronaviruses.
Absstract of: US12422397B1
The present invention generally includes methods, devices and/or kits for the detection of a COVID-19 infection in an individual by measuring the level or concentration or one or more ions present in a urine sample that is substantially free of COVID-19 RNA, antibodies, or antigen material.
Nº publicación: US2025288547A1 18/09/2025
Applicant:
AMERIMMUNE LLC [US]
Amerimmune LLC
Absstract of: US2025288547A1
Up-regulation of caspase has been found in COVID-19 patients, and also occurs in patients suffering from diabetes, hypertension, metabolic syndrome, and other conditions. Such up-regulation can be responsible for poor clinical outcomes in patients having such diseases or disorders, as such up-regulation leads to a process called pyroptosis: death and malfunction of immune system cells, particularly of certain types of lymphocytes. An inhibitor of caspase such as a caspase 1 inhibitor, or “pan-caspase” inhibitor (i.e., an inhibitor of multiple caspase types including caspase-1), can be used to treat COVID-19 patients or individuals at risk of infection, by limiting the malfunction of the immune system. A caspase-1 or pan-caspase inhibitor is advantageously administered before or very early in the course of infection by a positive-sense, single-stranded RNA virus such as SARS-COV, MERS-COV, or SARS-Cov-2.
BOPI
Electronic site
